CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25 TH Annual ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Northera™ (droxidopa) development program.
Mr. Oliveto's presentation will be webcast live and archived for 30 days on Chelsea's website, www.chelseatherapeutics.com.About Chelsea Therapeutics Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company, visit www.chelseatherapeutics.com
CONTACT: Investors: Fara Berkowitz/Susan Kim Argot Partners 212-600-1902 firstname.lastname@example.org email@example.com Media: David Pitts Argot Partners 212-600-1902 firstname.lastname@example.org